IRON — Disc Medicine, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1816736 ·
Last close
$64.92
Market Cap
$2.49B
52W High
$99.50
52W Low
$40.00
ADV30
506,498
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -65,075,000 | -59,532,000 | 735,071,000 | 98,676,000 | 90,907,000 |
| Mar 2026 | 0 | — | -69,524,000 | -63,504,000 | 750,213,000 | 88,913,000 | 61,784,000 |
| Dec 2025 | 0 | — | -66,970,000 | -60,531,000 | 806,879,000 | 91,145,000 | 67,053,000 |
| Sep 2025 | 0 | — | -67,696,000 | -62,321,000 | 630,456,000 | 140,664,000 | 57,066,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-197,536,000
Investing CF
$-93,419,000
Financing CF
$262,296,000
CapEx
$-933,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.54
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-633,222,000
Inventory
—
Receivables
—
ST Investments
$619,070,000
EBIT TTM
$-242,026,000
Pretax Income TTM
$-245,578,000
Interest Exp TTM
$3,552,000
Analysts
12
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -236,022,000 | -212,184,000 | 806,879,000 | 67,053,000 | 739,826,000 | -180,393,000 |
| Dec 2024 | 0 | -129,720,000 | -109,357,000 | 496,773,000 | 53,186,000 | 443,587,000 | -93,926,000 |
| Dec 2023 | 0 | -91,125,000 | -76,429,000 | 367,996,000 | 22,875,000 | 345,121,000 | -73,462,000 |
| Dec 2022 | 0 | -47,475,000 | -46,827,000 | 200,205,000 | 23,605,000 | 176,600,000 | -42,252,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-26,352,000
OpCashFlow TTM
$0
Assets (Latest)
$496,773,000
Forward EPS
$-7.26
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $65.00 · spot: $64.92 · call volume: 1,605 · put volume: 202
Expected Move to 2026-10-16:
±$9.37
(14.43%) —
implied range
$55.55 –
$74.29
· ATM straddle on $65.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GPCR | Structure Therapeutics Inc. | $2.50B | $35.06 | — |
| IMNM | Immunome Inc. | $2.46B | $21.68 | — |
| NRIX | Nurix Therapeutics, Inc. | $2.46B | $23.67 | — |
| HCM | HUTCHMED (China) Ltd | $2.46B | $14.13 | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | $2.59B | $44.60 | — |
News headlines (Yahoo Finance, 1h cache)
Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting
2026-09-09 23:25 · Yahoo
Disc Medicine to Participate in Upcoming Investor Conferences
2026-09-02 12:00 · Yahoo
Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
2026-08-31 22:00 · Yahoo
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says
2026-08-17 15:01 · Yahoo
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-30 12:30 · Yahoo
Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
2026-06-12 12:30 · Yahoo
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
2026-06-02 12:00 · Yahoo
How Investors May Respond To Disc Medicine (IRON) Expanding Pre-Approval Access To Bitopertin For Porphyria Patients
2026-06-01 14:07 · Yahoo
Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges
2026-05-26 04:04 · Yahoo
Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-05 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.